Related Experiment Videos
Breast cancer, blindness and melatonin
1Unit of Descriptive Epidemiology, International Agency for Research on Cancer, Lyon, France.
European Journal of Cancer (Oxford, England : 1990)
|January 1, 1992
Summary
Early blindness may lower breast cancer risk by altering melatonin secretion. This hypothesis, supported by animal studies, can be tested in humans to explore melatonin
Area of Science:
- Oncology
- Endocrinology
- Ophthalmology
Background:
- Breast cancer is a leading cause of mortality in women globally.
- Melatonin, a hormone produced by the pineal gland, exhibits oncostatic properties.
- Altered circadian rhythms and hormone secretion patterns are implicated in cancer development.
Purpose of the Study:
- To propose and explore the hypothesis that early-onset blindness may reduce breast cancer risk.
- To investigate the potential role of altered melatonin secretion in this hypothesized risk reduction.
- To suggest a human observational study design for testing this hypothesis.
Main Methods:
- Review of existing experimental evidence in animal models and in vitro studies.
- Proposal of a human observational study comparing breast cancer incidence in blind women versus the general female population.
- Consideration of adjusting for known breast cancer risk factors and assessing the impact of blindness characteristics (age at onset, duration, degree).
Main Results:
- Experimental evidence from animal and in vitro studies supports the proposed hypothesis.
- The hypothesis is testable in humans through a straightforward observational study design.
Conclusions:
- Early-onset blindness may be associated with a reduced risk of breast cancer.
- Altered melatonin secretion patterns due to blindness could be a mediating factor.
- Melatonin may hold potential as a natural oncostatic agent for cancer prevention strategies.